Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network

Detalhes bibliográficos
Autor(a) principal: Pinto, Daniel
Data de Publicação: 2019
Outros Autores: Rodrigues, Ana Paula, Nunes, Baltazar
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414
Resumo: Introduction: Type 2 diabetes is a major driver of pharmaceutical spending. We aimed to determine the proportion of new patients who begin treatment with each antidiabetic medicine class, if therapy was initiated by their family physician, if family physicians alter prescriptions initiated by other physicians, and to compare prescribing patterns of family physicians and other specialists.Material and Methods: Cohort-nested cross-sectional study within the Portuguese Sentinel Practice Network. Between 2014 and 2015, incident cases of type 2 diabetes were notified, thus reporting treatment, who made the initial prescription and if treatments initiated by other physicians were changed.Results: A total of 415 incident cases were notified. The initial prescription was made by Sentinel Practice Network physicians in 89.4% of cases (95% CI 86.0% - 92.0%). Metformin was most often chosen as the first treatment, prescribed to 85.5% of patients (95% CI 81.8% – 88.6%). Family physicians used less dipeptidyl peptidase-4 inhibitors (4.2% vs 30.3%, p < 0.001) and insulin (0.3% vs 12.1%, p < 0.001) compared to other specialists. Prescriptions initiated by others were changed in 4.5% of cases (95% CI 0.4% - 16.0%).Discussion: Prospective data collection is a major study strength, but few cases of treatment initiated by non-family physicians were notified. Data for disease severity was unavailable and could partly explain differences between family physicians and other specialists.Conclusion: Metformin was most often chosen as initial therapy, in line with Portuguese guideline recommendations. Sentinel Practice Network physicians diagnosed most cases, seldom changed prescriptions initiated by others, and had a different pattern of antidiabetic medicines use compared to other specialists.
id RCAP_351d89270e2e37293c57eefb01c07e49
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/10414
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice NetworkEscolhas Terapêuticas Iniciais para a Diabetes Tipo 2 na Rede de Médicos SentinelaDiabetes MellitusType 2/drug therapyHypoglycemic AgentsPortugalPrimary Health CareSentinel SurveillanceCuidados de Saúde PrimáriosDiabetes Mellitus Tipe 2/tratamentoHipoglicemiantesPortugalVigilância de Evento SentinelaIntroduction: Type 2 diabetes is a major driver of pharmaceutical spending. We aimed to determine the proportion of new patients who begin treatment with each antidiabetic medicine class, if therapy was initiated by their family physician, if family physicians alter prescriptions initiated by other physicians, and to compare prescribing patterns of family physicians and other specialists.Material and Methods: Cohort-nested cross-sectional study within the Portuguese Sentinel Practice Network. Between 2014 and 2015, incident cases of type 2 diabetes were notified, thus reporting treatment, who made the initial prescription and if treatments initiated by other physicians were changed.Results: A total of 415 incident cases were notified. The initial prescription was made by Sentinel Practice Network physicians in 89.4% of cases (95% CI 86.0% - 92.0%). Metformin was most often chosen as the first treatment, prescribed to 85.5% of patients (95% CI 81.8% – 88.6%). Family physicians used less dipeptidyl peptidase-4 inhibitors (4.2% vs 30.3%, p < 0.001) and insulin (0.3% vs 12.1%, p < 0.001) compared to other specialists. Prescriptions initiated by others were changed in 4.5% of cases (95% CI 0.4% - 16.0%).Discussion: Prospective data collection is a major study strength, but few cases of treatment initiated by non-family physicians were notified. Data for disease severity was unavailable and could partly explain differences between family physicians and other specialists.Conclusion: Metformin was most often chosen as initial therapy, in line with Portuguese guideline recommendations. Sentinel Practice Network physicians diagnosed most cases, seldom changed prescriptions initiated by others, and had a different pattern of antidiabetic medicines use compared to other specialists.Introdução: A diabetes tipo 2 tem um peso significativo nas despesas com medicamentos. Determinámos a proporção de novos doentes que iniciaram tratamento com cada classe de antidiabéticos, se o tratamento foi iniciado pelos médicos de família, se estes alteram as prescrições de outros médicos e comparámos padrões de prescrição de médicos de família e outros especialistas.Material e Métodos: Estudo transversal aninhado em coorte na Rede de Médicos Sentinela. Entre 2014 e 2015 casos incidentes de diabetes tipo 2 foram notificados, reportando o tratamento, quem fez a prescrição inicial e se tratamentos iniciados por outros médicos foram alterados.Resultados: Foram notificados 415 casos incidentes. Os Médicos Sentinela fizeram a prescrição inicial em 89,4% dos casos (IC 95% 86,0% - 92,0%). O tratamento inicial mais escolhido foi a metformina, em 85,5% dos doentes (IC 95% 81,8% - 88,6%). Os médicos de família utilizaram menos inibidores da dipeptidil peptidase-4 (4,2% vs 30,3%, p < 0,001) e insulina (0,3% vs 12,1%, p < 0,001) que outros especialistas. As prescrições iniciadas por outros foram alteradas em 4,5% dos casos (IC 95% 0,4% - 16,0%).Discussão: A colheita prospectiva dos dados é um ponto forte, mas foram notificados poucos casos de tratamento iniciado por outros especialistas. Dados sobre a gravidade da doença não estavam disponíveis e podem explicar parte das diferenças entre médicos de família e outros especialistas.Conclusão: A metformina foi o tratamento inicial mais escolhido, em linha com as recomendações das normas de orientação clínica Portuguesas. Os médicos da Rede Sentinela diagnosticaram a maioria dos casos, raramente alteraram prescrições iniciadas por outros e tiveram um padrão de prescrição diferente de outros especialistas.Ordem dos Médicos2019-05-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414oai:ojs.www.actamedicaportuguesa.com:article/10414Acta Médica Portuguesa; Vol. 32 No. 5 (2019): May; 375-380Acta Médica Portuguesa; Vol. 32 N.º 5 (2019): Maio; 375-3801646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414/5696https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414/10062https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414/10063https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414/10064Direitos de Autor (c) 2019 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessPinto, DanielRodrigues, Ana PaulaNunes, Baltazar2022-12-20T11:05:58Zoai:ojs.www.actamedicaportuguesa.com:article/10414Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:52.997267Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
Escolhas Terapêuticas Iniciais para a Diabetes Tipo 2 na Rede de Médicos Sentinela
title Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
spellingShingle Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
Pinto, Daniel
Diabetes Mellitus
Type 2/drug therapy
Hypoglycemic Agents
Portugal
Primary Health Care
Sentinel Surveillance
Cuidados de Saúde Primários
Diabetes Mellitus Tipe 2/tratamento
Hipoglicemiantes
Portugal
Vigilância de Evento Sentinela
title_short Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
title_full Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
title_fullStr Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
title_full_unstemmed Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
title_sort Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
author Pinto, Daniel
author_facet Pinto, Daniel
Rodrigues, Ana Paula
Nunes, Baltazar
author_role author
author2 Rodrigues, Ana Paula
Nunes, Baltazar
author2_role author
author
dc.contributor.author.fl_str_mv Pinto, Daniel
Rodrigues, Ana Paula
Nunes, Baltazar
dc.subject.por.fl_str_mv Diabetes Mellitus
Type 2/drug therapy
Hypoglycemic Agents
Portugal
Primary Health Care
Sentinel Surveillance
Cuidados de Saúde Primários
Diabetes Mellitus Tipe 2/tratamento
Hipoglicemiantes
Portugal
Vigilância de Evento Sentinela
topic Diabetes Mellitus
Type 2/drug therapy
Hypoglycemic Agents
Portugal
Primary Health Care
Sentinel Surveillance
Cuidados de Saúde Primários
Diabetes Mellitus Tipe 2/tratamento
Hipoglicemiantes
Portugal
Vigilância de Evento Sentinela
description Introduction: Type 2 diabetes is a major driver of pharmaceutical spending. We aimed to determine the proportion of new patients who begin treatment with each antidiabetic medicine class, if therapy was initiated by their family physician, if family physicians alter prescriptions initiated by other physicians, and to compare prescribing patterns of family physicians and other specialists.Material and Methods: Cohort-nested cross-sectional study within the Portuguese Sentinel Practice Network. Between 2014 and 2015, incident cases of type 2 diabetes were notified, thus reporting treatment, who made the initial prescription and if treatments initiated by other physicians were changed.Results: A total of 415 incident cases were notified. The initial prescription was made by Sentinel Practice Network physicians in 89.4% of cases (95% CI 86.0% - 92.0%). Metformin was most often chosen as the first treatment, prescribed to 85.5% of patients (95% CI 81.8% – 88.6%). Family physicians used less dipeptidyl peptidase-4 inhibitors (4.2% vs 30.3%, p < 0.001) and insulin (0.3% vs 12.1%, p < 0.001) compared to other specialists. Prescriptions initiated by others were changed in 4.5% of cases (95% CI 0.4% - 16.0%).Discussion: Prospective data collection is a major study strength, but few cases of treatment initiated by non-family physicians were notified. Data for disease severity was unavailable and could partly explain differences between family physicians and other specialists.Conclusion: Metformin was most often chosen as initial therapy, in line with Portuguese guideline recommendations. Sentinel Practice Network physicians diagnosed most cases, seldom changed prescriptions initiated by others, and had a different pattern of antidiabetic medicines use compared to other specialists.
publishDate 2019
dc.date.none.fl_str_mv 2019-05-31
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414
oai:ojs.www.actamedicaportuguesa.com:article/10414
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/10414
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414/5696
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414/10062
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414/10063
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10414/10064
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2019 Acta Médica Portuguesa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2019 Acta Médica Portuguesa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 32 No. 5 (2019): May; 375-380
Acta Médica Portuguesa; Vol. 32 N.º 5 (2019): Maio; 375-380
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130648422645760